{"href":"https://api.simplecast.com/oembed?url=https%3A%2F%2Fscience-with-a-twist.simplecast.com%2Fepisodes%2Fdisrupting-the-status-quo-Jw79qWFp","width":444,"version":"1.0","type":"rich","title":"Disrupting the Status Quo: The Importance of Diversity in Clinical Trials ","thumbnail_width":300,"thumbnail_url":"https://image.simplecastcdn.com/images/22f4253f-b311-48a5-875e-855841124375/3a0862a6-e4b9-4ad3-b33c-f96931c3cd4f/swat-cover-art.jpg","thumbnail_height":300,"provider_url":"https://simplecast.com","provider_name":"Simplecast","html":"<iframe src=\"https://player.simplecast.com/1e39b463-ea97-4ab5-a46c-972d7d958068\" height=\"200\" width=\"100%\" title=\"Disrupting the Status Quo: The Importance of Diversity in Clinical Trials \" frameborder=\"0\" scrolling=\"no\"></iframe>","height":200,"description":"We live in an increasingly diverse world, and in order to deliver the best quality healthcare, we need to embrace and improve patient diversity in clinical trials. \n\nBut how do we improve clinical research and expand treatment access to a more diverse patient population? In the second and final episode of our Clinical Research Series on the Science with a Twist podcast, our host Lloryn Hubbard welcomes Nik Kolatkar, VP of Scientific Operations & Evidence Generation at Genentech. They discuss the impact of inclusive research on drug development and decentralized and virtual study approaches that can reduce barriers and improve clinical trial participation for disenfranchised groups. "}